Comparative Effectiveness and Safety of Rivaroxaban and Warfarin Among Nonvalvular Atrial Fibrillation (NVAF) Patients with Obesity and Polypharmacy in the United States (US)

INTRODUCTION: Current evidence indicates that rivaroxaban may be a safe and effective alternative to warfarin among patients with nonvalvular atrial fibrillation (NVAF) and obesity. However, evidence regarding the impact of polypharmacy is limited in this population. The present study evaluated the...

Descripción completa

Detalles Bibliográficos
Autores principales: Berger, Jeffrey S., Laliberté, François, Kharat, Akshay, Lejeune, Dominique, Moore, Kenneth Todd, Jung, Young, Lefebvre, Patrick, Ashton, Veronica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8280049/
https://www.ncbi.nlm.nih.gov/pubmed/34031859
http://dx.doi.org/10.1007/s12325-021-01746-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8280049/
https://www.ncbi.nlm.nih.gov/pubmed/34031859
http://dx.doi.org/10.1007/s12325-021-01746-2

Ejemplares similares